3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
33
Ovarian Neoplasms
9
Breast Neoplasms
9
Pancreatic Neoplasms
8
Metastatic Castration-resistant Prostate Cancer
5
Carcinoma, Renal Cell
5
Urinary Bladder Neoplasms
4
Neoplasm Metastasis
4
Triple Negative Breast Neoplasms
3
Sarcoma
3
Lymphoma, Non-Hodgkin
3
Endometrial Neoplasms
3
Carcinoma, Transitional Cell
3
Wilms Tumor
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Prostatic Neoplasms, Castration-Resistant
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Medulloblastoma
2
Lung Neoplasms
2
Histiocytosis, Langerhans-Cell
2
Hereditary Sensory and Autonomic Neuropathies
2
Hepatoblastoma
2
Glioma
2
Ependymoma
2
Central Nervous System Neoplasms
2
Castration-Resistant Prostate Carcinoma
2
Xanthogranuloma, Juvenile
1
Interventions
tislelizumab
2
Cystectomy
2
vistusertib
1
toripalimab
1
olaparib
1
liposomal doxorubicin
1
durvalumab
1
disitamab vedotin
1
danvatirsen
1
adavosertib
1
Surgical Procedures, Operative
1
Rutin
1
Radiation
1
RC48 antibody
1
Neoadjuvant Therapy
1
Gemcitabine
1
Cisplatin
1
Chemoradiotherapy
1
AZD4547
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Muscle Invasive Bladder Cancer
×
olaparib
×
Genitourinary
×
Clear all
NCT02546661
2025-12-29
BISCAY
AstraZeneca
Phase 1
Active not recruiting
117 enrolled